Influence of Access, Anticoagulant, and Bleeding Definition on Outcomes of Primary Percutaneous Coronary Intervention: Early Experience of an US Academic Center

M. K. Bheemarasetti; S. Shawar; S. Chithri; W. I. Khalife; U. M. Rangasetty; K. Fujise; S. A. Gilani

doi:10.1055/s-0034-1394158

International Journal of Angiology, Table of Contents

Int J Angiol 2015; 24(01): 11-18
DOI: 10.1055/s-0034-1394158

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Influence of Access, Anticoagulant, and Bleeding Definition on Outcomes of Primary Percutaneous Coronary Intervention: Early Experience of an US Academic Center

M. K. Bheemarasetti

¹Division of Cardiology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas

,

S. Shawar

¹Division of Cardiology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas

,

S. Chithri

¹Division of Cardiology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas

,

W. I. Khalife

¹Division of Cardiology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas

,

U. M. Rangasetty

¹Division of Cardiology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas

,

K. Fujise

¹Division of Cardiology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas

,

S. A. Gilani

¹Division of Cardiology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas

› Author Affiliations

Abstract

Background We aimed to carry out comparison of different bleeding avoidance strategies in doing primary percutaneous coronary intervention (PPCI) using either radial or femoral as access of choice and either bivalirudin or unfractionated heparin as anticoagulant of choice. In this analysis, we analyzed the influence of major bleeding definition on bleeding outcomes as well.

Methods We did a retrospective analysis of 139 patients with ST-segment elevation myocardial infarction (STEMI) who had PPCI in our academic center from January 2010 till October 2013. The primary outcome at 30 days was a composite of death from any cause or stent thrombosis or non-coronary artery bypass grafting (CABG) related major bleeding (CathPCI Registry definition) and secondary outcomes were individual components of primary outcome and the hospital length of stay.

Results There was no significant difference among different access/anticoagulant combinations with regards to primary outcome (22% in radial/bivalirudin vs. 5% in radial/heparin vs. 17% in femoral/bivalirudin vs. 28% in femoral/heparin group; p = 0.2) as well as its individual components except the hospital length of stay (2.56 vs. 3 vs. 3.97 vs. 4.4 days each; p < 0.0001). The overall rate of major bleeding was 11.5%. When we use HORIZON-AMI bleeding definition, it went up to 25 % due to one particular component (p < 0.004).

Conclusions This single center observational study doing PPCI did not show any superiority of one bleeding avoidance strategy over others with regard to primary outcome and its individual components except the hospital length of stay. It also shows the importance of bleeding definition on bleeding outcomes.

Keywords

radial access - bivalirudin - bleeding definition

Full Text

References

References
1 Stone GW, Witzenbichler B, Guagliumi G , et al; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358 (21) 2218-2230
2 Karrowni W, Vyas A, Giacomino B , et al. Radial versus femoral access for primary percutaneous interventions in ST-segment elevation myocardial infarction patients: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv 2013; 6 (8) 814-823
3 Baklanov DV, Kim S, Marso SP, Subherwal S, Rao SV. Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention: analysis from the national cardiovascular data registry. Circ Cardiovasc Interv 2013; 6 (4) 347-353
4 Sciahbasi A, Rigattieri S, Cortese B , et al. Bivalirudin or heparin in primary angioplasty performed through the transradial approach: results from a multicentre registry. Eur Heart J Acute Cardiovasc Care 2014; 3 (3) 268-274
5 Cutlip DE, Windecker S, Mehran R , et al; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115 (17) 2344-2351
6 Jolicoeur EM, O'Neill WW, Hellkamp A , et al; APEX-AMI Investigators. Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Eur Heart J 2009; 30 (21) 2575-2583
7 Doyle BJ, Rihal CS, Gastineau DA, Holmes Jr DR. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol 2009; 53 (22) 2019-2027
8 Rao SV, O'Grady K, Pieper KS , et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96 (9) 1200-1206
9 Romagnoli E, Biondi-Zoccai G, Sciahbasi A , et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. J Am Coll Cardiol 2012; 60 (24) 2481-2489
10 Jolly SS, Yusuf S, Cairns J , et al; RIVAL trial group. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011; 377 (9775) 1409-1420
11 Sanborn TA, Ebrahimi R, Manoukian SV , et al. Impact of femoral vascular closure devices and antithrombotic therapy on access site bleeding in acute coronary syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Circ Cardiovasc Interv 2010; 3 (1) 57-62
12 Steg PG, van 't Hof A, Hamm CW , et al; EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013; 369 (23) 2207-2217
13 Mehran R, Rao SV, Bhatt DL , et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
14 Jan KM, Chien S, Bigger Jr JT. Observations on blood viscosity changes after acute myocardial infarction. Circulation 1975; 51 (6) 1079-1084
15 Rao AK, Pratt C, Berke A , et al. Thrombolysis in Myocardial Infarction (TIMI) Trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11 (1) 1-11
16 Bovill EG, Terrin ML, Stump DC , et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991; 115 (4) 256-265
17 Muthusamy P, Busman DK, Davis AT, Wohns DH. Assessment of clinical outcomes related to early discharge after elective percutaneous coronary intervention: COED PCI. Catheter Cardiovasc Interv 2013; 81 (1) 6-13
18 Rao SV, Kaul PR, Liao L , et al. Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 2008; 155 (2) 369-374